الفهرس 
Uterine MyomasOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
Uterine myomata are the most frequent tumours of the female genital
tract affecting 20-50% of all women, with an increased incidence in the later
years of a woman‘s reproductive life. Myoma is mostly asymptomatic. Size
and location are the main factors that determine if a myoma leads to
symptoms and problems. Important symptoms include abnormal uterine
bleeding, abdominal discomfort, bloating, painful defecation, backache,
urinary frequency or retention and infertility.
Patients have multiple options in the management of uterine myomas
including observation, medical therapy, uterine artery embolization, high
intensity focused ultrasound ablation and as well as surgical methods like
myomectomy and hysterectomy. Surgical removal is necessary when the
myoma is symptomatic and resistant to medical management or interferes
with reproduction. Although uterine artery embolization is now an effective
way for managing symptomatic uterine myomas but its effect on future
conception remains unclear.
There are various pharmacological and nonpharmacological methods
have been tested to control haemorrhage during myomectomy. However, no
specific procedure or drug has been identified as the optimum management
method to decrease bleeding during these operations.
This study was conducted at Tanta University Hospitals aiming to
compare between the effect of intramyometrial injection of carbetocin versus
vasopressin for reduction of blood loss in cases of myomectomy operations.
We included a total of 60 patients diagnosed with uterine fibroids, and they
were divided into three equal groups; Control group (20 cases), Carbetocin
group (20 cases) and Vasopressin group (20 cases).